The CEA -/lo colorectal cancer cell population harbors cancer stem cells and metastatic cells
Supplementary Materials Flow cytometric analysis
To identify CEA + and CEA -/lo cells in CRC specimens or xengrafts, tissues were processed into single cell suspension as described above. Cells were stained with biotinylated CEA antibodies (10 μl/10 7 cells) at 4°C for 15min, followed by stained with anti-biotin FITC secondary antibodies (10 μl/10 7 cells), EpCAM-APC (10 μl/10 7 cells) and propidium iodide (50 μg/mL; Sigma, MO, USA) at 4°C for 15 min. Samples were analyzed using BD FACS Aria II (BD Biosciences, CA, USA).
Cell-cycle analysis was performed for purified CEA + and CEA -/lo xhCRC cells, fixed in ice-cold 70% ethanol at 4°C overnight. Cells were then washed with PBS and incubated with PBS containing propidium iodide (50ug/ ml; Sigma, USA) and RNase (10ug/ml; Sigma, USA) at room temperature for 30 minutes. Samples were analyzed using BD FACS Aria II.
Ki-67 expression was performed for purified CEA + and CEA -/lo xhCRC cells, fixed in ice-cold 70% ethanol at −20°C for 1 hour. Cells were then washed with PBS and incubated with anti-Ki-67 antibodies (10 μl/10 7 cells; Miltenyi Biotech) at room temperature for 30 minutes. After washed with PBS twice, cells were analyzed using BD FACS Aria II.
Magnetic sorting and fluorescence-activated cell sorting
Magnetic cell separation was performed on LoVo and SW48 cells using biotinylated CEA antibodies (Thermo Scientific, MA, USA) and anti-biotin microbeads. Quality of sorting of both CEA + and CEA -/lo fractions was verified by flow cytometry and/or immunofluorescence staining with mouse anti human CEA monoclonal antibodies, followed by labeled with PE-conjugated goat anti mouse antibodies (Dako, Denmark).
Fluorescence-activated cell sorting was performed on xenograft tumors. 
Immunofluorescence microscopy
Immunofluorescence was performed on cytospins as described [1] . The following antibodies were used: CEA (1:100; Thermo Scientific, UK), EpCAM (1:100, Miltenyi Biotech), cytokeratin 20 (1:100; Dako, Denmark). Briefly, cells were plated on the glass coverslips overnight. Cells were then fixed by 4% paraformaldehyde (PFA) for 10 min at room temperature. After blocking with 5% (w/v) bovine serum albumin in PBS, cell were incubated with primary antibodies at 4°C overnight, followed by staining with secondary antibodies conjugated to biotin (Miltenyi Biotech) or Alexa Flour 488 (Jackson ImmunoResearch Laboratories, PA, USA) at room temperature for 2 hours. Finally, nuclei were stained with DAPI (4',6-Diamidino-2-phenylindole, Sigma) for 10min at room temperature. Cells were visualized by using a fluorescence microscope (TRRFM, Olympus) or a confocal microscope (FV1000, Olympus).
In vivo limiting dilution assays and serial tumor transplatation in NOD/SCID mice
For limiting dilution assays, varying number of CEA + and CEA -/lo cells from different CRC cell lines or xenograft tumors were implanted into the back of Balb/c-nu mice or NOD/SCID mice (see Table 2 for the injected cell numbers). The frequency of tumor-initiating cells and statistical significance were examined using the Extreme Limiting Dilution Analysis (ELDA) software at the application website http://bioinf.wehi.edu.au/software/elda/index.html.
For serial tumor transplantation in NOD/SCID mice, CEA + and CEA -/lo cells were purified from xhCRC and 10,000 (+10K or −10K) cells each were implanted subcutaneously in female NOD/SCID mice (n = 5 per group). The first-generation (1°) tumors were harvested 40 days later. CEA + cells were purified from one tumor originally derived from purified CEA + cells whereas CEA -/lo cells were from one tumor derived initially from purified CEA -/lo cells. And then, 10,000 cells each were implanted subcutaneously to generate secondary (2°) tumors in NOD/SCID mice.
Clonal culture, sphere-formation assays and organoid cultures
Basic procedures for clonal culture and sphereformation assays were previously described [2, 3] . For clonal culture, purified CEA + and CEA -/lo cells were plated in a six-well culture plate at a density of 100, 200 or 300 cells/well. Clones with ≥ 50 cells were scored ~2 weeks after plating. The results were expressed as cloning efficiency (%). For sphere-formation assays in CRC cell lines, xenografts, purified CEA + and CEA -/lo cells were plated at 200 cells/well (SW48 and LoVo cells) or 1,000 cells/well (xenografts) in ultra-low attachment (ULA) plates. Spheres that raised within 1-2 weeks and ≥ 50μm were presented as clonogenicity (% or ‰). For serial sphere-formation assays, the first-generation spheres were harvested, disaggregated with 0.025% trypsin/EDTA, triturated with a 27-G needle, filtered through a 40-μm mesh, and replated as above. This process was repeated for up to 3 generations. When cells were treated with exogenous CEA, different doses of recombinant human CEA protein (R&D systems) were added every 3 days. For organoid cultures, the Matrigel (GFR, phenol free, BD bioscience, USA) were first polymerized for 10 minutes at 
Anoikis and FACS analysis
Anoikis was induced as described [4] . Briefly, purified CEA + and CEA -/lo cells were seeded at a density of 20,000 cells per well (500 μL) in a 24-well ultra-low attachment culture plate (Corning, USA). After 4 days, cells were harvested and resuspended in 500 μL binding buffer supplemented with 5 μL Annexin-V-FITC and 5 μL propidium iodide according to the instruction of Annexin-V-FITC Apoptosis Detection Kit (KeyGEN Biotech, Nanjing, China). The percentage of cells that underwent anokis was defined as the Annexin-V or propidium iodide positive population analyzed on BD FACS Aria II.
To explore the effects of exogenous CEA on CEA + and CEA -/lo CRC cells, cells were purified and plated as described above and recombinant human CEA protein (1000 ng/mL; R&D systems) was added every 3 days. After 6 days, cells were harvested and analyzed by flow cytometry as described above.
Experimental liver and lung metastasis model for colorectal cancer
Liver metastases were generated by injecting 100,000 purified SW48 CEA + and CEA -/lo cells into spleens of NOD/SCID mice. After 8 weeks, livers were removed and examined for metastatic lesions. Lung metastasis was performed by injecting 1,000,000 purified xhCRC CEA + and CEA -/lo cells through tail veins of NOD/SCID mice. After 8 weeks, lungs were removed and examined for metastatic lesions.
Quantitative RT-PCR and western blot analysis
Total RNA was extracted using RNAiso Plus (Takara, Japan) and then complementary DNA (cDNA) was synthesized using the Mixima First Strand cDNA Synthesis Kit (Thermo Scientific, MA, USA). Quantitative RT-PCR analysis was carried out using an ABI PRISM 7300 Sequence Detection System instrument with Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific, MA, USA) according to the manufacturer's instructions. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. The details of primers are shown below: GAPDH forward: 5ʹ-TCGTGGAAGGACTCATGACC-3ʹ, GAPDH reverse 5ʹ-TCCACCACCCTGTTGCTGTA-3ʹ, CD44 forward 5ʹ-AGCAACCAAGAGGCAAGAAA-3ʹ, CD44 reverse 5ʹ-GTGTGGTTGAAATGGTGCTG-3ʹ, IGF1R forward 5ʹ-TCGACATCCGCAACGACTATC-3ʹ, IGF1R reverse 5ʹ-CCAGGGCGTAGTTGTAGAAGAG-3ʹ.
Purified cells were lysed in NP40 protein lysis buffer containing a protease inhibitor mixture (Sigma, MO, USA) and separated by sodium dodecyl polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes. After blocking with 5% BSA in 0.01 M TBS (pH 7.5) containing 0.5% Tween 20 (TBST), the membranes were incubated with the appropriate primary antibodies at 4°C overnight, followed by incubated with horseradish peroxidase-conjugated goat anti-rabbit-IgG or goat anti-mouse IgG secondary antibodies for 2 hours at room temperature. Finally, the protein bands were visualized using SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific, MA, USA). + and CEA -/lo CRC cells (i.e., SW48, LoVo, xhCRC) were acutely purified, and then seeded in ultra-low attachment wells. Primary spheres were formed at 1~2 weeks after plating. Note that CEA -/lo cells formed more spheres than corresponding CEA + cells during subsequent serial passaging. And more significantly, CEA + xhCRC lost sphere-propagating capacity by 2° generation, whereas CEA -/lo CRC cells gradually increased in the sphere-propagating capacity. Scale bars: 100 μm. + and CEA -/lo CRC cells (i.e., SW48, LoVo, xhCRC) were acutely purified, and then seeded at a density of 20,000 cells/well in ultra-low attachment 24-wells. After 4 days anchorage-independent culture, cell apoptosis was evaluated by flow cytometry. The percentage of cells that resistant to anokis was defined as the Annexin-V and propidium iodide negative population. (B-D) Single purified CEA + and CEA -/lo CRC cells (i.e., SW48, LoVo, xhCRC) were seeded in ultra-low attachment 24-wells as described above. Recombinant human CEA (1000 ng/mL) were added every 3 days. After 6 days anchorage-independent culture, cell apoptosis was evaluated using FACS. CEA molecule protected CEA -/lo cells from anoikis, whereas exogenous CEA had little effects on CEA + cells. CSPP1, RAN, PLK4, RBMS3, CCND2, POLA2 Multi-drug resistance ABCC5, ABCG1, ABCB10 Note. CEA + and CEA -/lo cells were purified from xenograft tumor derived from CRC patient (xhCRC) and were applied for microarray analysis. Genes were considered differential expressed if the fold change was greater than 2.0 fold and the P-value was less than 0.05. Genes that play negative roles in regulation were marked in red. 
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